E 12.7 masina le ola fa'a-Median, e 7.2 masina le fa'aola le alualu i luma o le puipuiga (iPFS), ma le fua faatatau o le ola 1-tausaga e 55%. I le taimi o suʻesuʻega, e 12 tagata gasegase o loʻo ola pea ma e toʻalua tagata gasegase o loʻo faia togafitiga. Saogalemu ma tali tali e tutusa ma le faʻafouga muamua mai ia Me 2021.

O le interleukin-1 receptor accessory protein (IL1RAP)-binding antibody nadunolimab o le polokalame taʻitaʻi a Cantargia ma o loʻo suʻesuʻeina i le tele o suʻesuʻega faʻataʻitaʻiga e iloilo ai le tele o togafitiga faʻapipiʻi i ituaiga eseese o le kanesa, ma le PDAC e sili ona suʻesuʻeina. E oʻo mai i le taimi nei, e sili atu i le 70 PDAC maʻi na maua togafitiga faʻatasi ma le nadunolimab faʻatasi ma gemcitabine ma nab-paclitaxel i le vaega I / IIa suʻesuʻega falemaʻi CANFOUR. O le faʻafouga na lipotia i aso nei e faʻavae i luga o le vaega muamua o 33 tagata gasegase na iloiloina mo le aoga.

I le suʻesuʻega le tumau faʻafouina, faʻatasi ai ma se taimi mulimulitaʻi umi atu nai lo faitauga muamua e mafua ai se suʻesuʻega sili atu le malosi, o le ola faʻasalalau o le 12.7 masina ma le 1-tausaga o le ola ola e 55%. Median iPFS e 7.2 masina ma le 6-masina iPFS o le 56%. I le faʻatusatusaina, o faʻamatalaga faʻasolopito i le laina muamua o togafitiga o le PDAC maʻi ma le gemcitabine ma le nab-paclitaxel o loʻo faʻaalia ai le ola o le 8.5 masina ma le 1-tausaga le olaola o le 35%, ma le PFS o le 5.5 masina ma le 6-masina PFS o le 44% 1. I le taimi o suʻesuʻega, e toʻalua gasegase o loʻo faia pea togafitiga ma 12 tagata gasegase o loʻo soifua pea. O le mea e malie ai, 6 maʻi (18%) i le faʻataʻitaʻiga na maua togafitiga mo le umi atu ma le tasi le tausaga.

O le talaaga o le saogalemu e matua'i le suia lava mai le fa'afouga muamua ma le a'afiaga o le neutropenia ma le febrile neutropenia e maualuga atu nai lo le fa'amoemoe mai le chemotherapy na'o. Fa'ailoa, febrile neutropenia e na'o le ta'amilosaga muamua o togafitiga e matauina ma e mafai ona puipuia tele i togafitiga fa'ama'i e le granulocyte growth factor G-CSF. O le mea e malie ai, e leai ni faʻafitauli ogaoga (vasega 3 poʻo le maualuga) neuropathy, o se itu masani o le gemcitabine ma le nab-paclitaxel, na matauina.

E le gata i lea, e 40 isi gasegase PDAC o loʻo suʻesuʻeina i se faʻaopoopoga o le suʻega CANFOUR. O fa'ai'uga mai lea vaega ole su'esu'ega e fa'amoemoe e matua mo le tu'uina atu ile H1 2022. O lo'o sauni nei Cantargia mo se fa'ata'ita'iga fa'afuase'i ma e ono fa'atauaina ile laina muamua ole kanesa pancreatic. O le a fa'aalia le mamanu ma taimi fa'atulagaina pe a mae'a talanoaga sauniuni ma pulega tetele fa'atonutonu.

OA MEA E AVEA MAI LENEI TUSI:

In the updated interim analysis, with a longer follow-up period than previous readouts resulting in a more robust analysis, median survival is 12.
The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody nadunolimab is Cantargia’s lead program and is investigated in multiple clinical trials evaluating various combination therapy regimens in different forms of cancer, with PDAC being the most extensively studied.
In comparison, historical data in first line treatment of PDAC patients with gemcitabine and nab-paclitaxel show median survival of 8.